{"id":70513,"date":"2026-07-23T21:59:59","date_gmt":"2026-07-23T13:59:59","guid":{"rendered":"https:\/\/flcube.com\/?p=70513"},"modified":"2026-07-23T22:00:00","modified_gmt":"2026-07-23T14:00:00","slug":"summit-therapeutics-and-arcus-biosciences-launch-global-trial-of-ivonescimab-casdatifan-combination-for-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70513","title":{"rendered":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Summit Therapeutics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/SMMT:NASDAQ\">NASDAQ: SMMT<\/a>), in partnership with <strong>Akeso, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/9926:HKG\">HKG: 9926<\/a>), announced a strategic collaboration with <strong>Arcus Biosciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RCUS:NYSE\">NYSE: RCUS<\/a>) to advance an <strong>international multi-center clinical study<\/strong> evaluating the combination of <strong>ivonescimab<\/strong> and <strong>casdatifan<\/strong> for the treatment of <strong>clear cell renal cell carcinoma (ccRCC)<\/strong>. The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.<\/p>\n\n\n\n<h2 id=\"h-collaboration-framework\" class=\"wp-block-heading\">Collaboration Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Lead Companies<\/strong><\/td><td>Summit Therapeutics Inc. (NASDAQ: SMMT) &amp; Arcus Biosciences, Inc. (NYSE: RCUS)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Akeso, Inc. (HKG: 9926)<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>International multi-center clinical trial<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Clear cell renal cell carcinoma (ccRCC)<\/td><\/tr><tr><td><strong>Treatment Setting<\/strong><\/td><td>First-line therapy for most common ccRCC form<\/td><\/tr><tr><td><strong>Therapeutic Goal<\/strong><\/td><td>TKI-free combination regimen with extended survival potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-ivonescimab\" class=\"wp-block-heading\">Ivonescimab<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: First-in-class PD-1\/VEGF bispecific antibody<\/li>\n\n\n\n<li><strong>Dual Targeting<\/strong>: Simultaneously inhibits PD-1 immune checkpoint and VEGF angiogenesis pathway<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Advanced clinical development by Akeso, partnered with Summit Therapeutics for global markets<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses both immune evasion and tumor vascularization in single molecule<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-casdatifan\" class=\"wp-block-heading\">Casdatifan<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class<\/strong>: Small-molecule inhibitor of hypoxia-inducible factor 2-alpha (HIF-2\u03b1)<\/li>\n\n\n\n<li><strong>Target<\/strong>: HIF-2\u03b1, a key transcription factor driving ccRCC progression<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: Arcus Biosciences&#8217; proprietary HIF-2\u03b1 inhibitor program<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Disrupts hypoxia signaling pathway fundamental to ccRCC biology<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-combination-synergy\" class=\"wp-block-heading\">Combination Synergy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complementary Mechanisms<\/strong>: Triple-pathway inhibition targeting immune checkpoint (PD-1), angiogenesis (VEGF), and hypoxia signaling (HIF-2\u03b1)<\/li>\n\n\n\n<li><strong>TKI-Free Approach<\/strong>: Eliminates tyrosine kinase inhibitor toxicity while maintaining therapeutic efficacy<\/li>\n\n\n\n<li><strong>Tolerability Profile<\/strong>: Designed to improve patient quality of life through reduced adverse event burden<\/li>\n\n\n\n<li><strong>Survival Potential<\/strong>: Preclinical data suggest synergistic anti-tumor activity with potential for extended overall survival<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ccRCC Treatment Landscape<\/strong>: Addresses $4.2 billion global market with significant unmet need for better-tolerated first-line therapies<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: First combination to simultaneously target PD-1, VEGF, and HIF-2\u03b1 pathways<\/li>\n\n\n\n<li><strong>Commercial Opportunity<\/strong>: Potential to capture substantial market share from current TKI-based standard of care<\/li>\n\n\n\n<li><strong>Partnership Leverage<\/strong>: Combines Summit&#8217;s\/Akeso&#8217;s bispecific antibody expertise with Arcus&#8217;s HIF-2\u03b1 inhibitor platform<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: Global trial design supports simultaneous regulatory submissions in major markets<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Targets approximately 75,000 new ccRCC cases annually in U.S. and EU combined<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-context\" class=\"wp-block-heading\">Strategic Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This collaboration represents a convergence of three innovative approaches to ccRCC treatment:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Bispecific Antibody Technology<\/strong>: Ivonescimab&#8217;s dual-targeting capability reduces combination complexity<\/li>\n\n\n\n<li><strong>Hypoxia Pathway Inhibition<\/strong>: Casdatifan addresses the genetic driver of ccRCC (VHL mutations leading to HIF-2\u03b1 stabilization)<\/li>\n\n\n\n<li><strong>TKI-Free Paradigm<\/strong>: Eliminates class-specific toxicities including hypertension, hand-foot syndrome, and fatigue<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">The partnership leverages complementary strengths, with Summit\/Akeso contributing their advanced bispecific platform and Arcus providing specialized expertise in hypoxia pathway inhibition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and partnership execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[360,700,29,850,1181,1403,18,712],"class_list":["post-70513","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-akeso-biopharma","tag-arcus-biosciences","tag-combination-therapy","tag-hkg-9926","tag-nasdaq-smmt","tag-nyse-rcus","tag-pd-1-l1","tag-summit-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70513\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70513\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T13:59:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T14:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma\",\"datePublished\":\"2026-07-23T13:59:59+00:00\",\"dateModified\":\"2026-07-23T14:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513\"},\"wordCount\":480,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Akeso Biopharma\",\"Arcus Biosciences\",\"Combination therapy\",\"HKG: 9926\",\"NASDAQ: SMMT\",\"NYSE: RCUS\",\"PD-1\\\/L1\",\"Summit Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70513#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70513\",\"name\":\"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-23T13:59:59+00:00\",\"dateModified\":\"2026-07-23T14:00:00+00:00\",\"description\":\"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70513\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70513#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70513","og_locale":"en_US","og_type":"article","og_title":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma","og_description":"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.","og_url":"https:\/\/flcube.com\/?p=70513","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-23T13:59:59+00:00","article_modified_time":"2026-07-23T14:00:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70513#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70513"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma","datePublished":"2026-07-23T13:59:59+00:00","dateModified":"2026-07-23T14:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70513"},"wordCount":480,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Akeso Biopharma","Arcus Biosciences","Combination therapy","HKG: 9926","NASDAQ: SMMT","NYSE: RCUS","PD-1\/L1","Summit Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70513#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70513","url":"https:\/\/flcube.com\/?p=70513","name":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-23T13:59:59+00:00","dateModified":"2026-07-23T14:00:00+00:00","description":"Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic collaboration with Arcus Biosciences, Inc. (NYSE: RCUS) to advance an international multi-center clinical study evaluating the combination of ivonescimab and casdatifan for the treatment of clear cell renal cell carcinoma (ccRCC). The trial will include first-line treatment evaluation for the most common form of ccRCC, representing a potential paradigm shift toward tyrosine kinase inhibitor (TKI)-free combination therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70513#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70513"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70513#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70513"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70513\/revisions"}],"predecessor-version":[{"id":70514,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70513\/revisions\/70514"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}